Unlock instant, AI-driven research and patent intelligence for your innovation.

Biocatalytic synthesis of nostoc anticancer agents

A compound and epoxide technology, applied in the fields of drug combination, organic chemistry, anti-tumor drugs, etc., can solve the problems of leading compound synthesis hindering exploration and other problems

Pending Publication Date: 2022-06-21
RGT UNIV OF MICHIGAN
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

32-36 Although there is still a lot of interest in candocin as an anticancer agent, challenges in lead compound optimization and expensive synthetic work for its production hamper exploration.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biocatalytic synthesis of nostoc anticancer agents
  • Biocatalytic synthesis of nostoc anticancer agents
  • Biocatalytic synthesis of nostoc anticancer agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0108] Materials and Methods

[0109] Chemical reagents and solvents were purchased from EMD Millipore, Sigma-Aldrich, Oakwood, Combi blocks, Chem impex and Thermo-Fisher Scientific unless otherwise stated. Kanamycin sulfate and isopropyl-beta-D-thiogalactoside (IPTG) were obtained from Gold Biotechnology. Lysozyme was purchased from RPI. Imidazole was purchased from AK Scientific. Amicon Ultra centrifugal filters for protein concentration were purchased from GE Healthcare.

[0110] Deionized water was obtained from a Milli-Q system (EMDMilipore) using a Q-Gard 2 / Quantum Ex Ultrapure organex column. Media components for E. coli growth were purchased from EMD Milipore, Sigma-Aldrich and Thermo-Fisher Scientific. Glycerol was purchased from BDH via VWR. LB broth and LB agar (Miller) were purchased from EMD Millipore in pre-granulated form. TB broth was prepared from separately purchased components and consisted of 4% v / v glycerol. Autoclave or sterile filter media and sol...

Embodiment 2

[0116] chemical synthesis

[0117] 1. Unit A synthesis

[0118] like image 3 As shown in B, compound 2 was synthesized in two steps from commercially available S1. All spectra are consistent with previous literature reports. 1,2

[0119] (R)-4-benzyl-3-((2R,3S)-3-hydroxy-5-((4-methoxybenzyl)oxy)-2vinylvaleryl)oxa oxazolidin-2-one (S3).

[0120] To a three-necked flask with an internal temperature probe was added 1 (7.502 g, 30.58 mmol, 1 equiv) in CH 2 Cl 2 (305 mL, 0.1 M) and cooled to -78 °C. This was treated with dibutylboron triflate (1 M in DCM, 33.64 mL, 33.64 mmol, 1.1 equiv) and Et 3 Treat with N (6.02 mL, 42.8 mmol, 1.4 equiv). After 1 hour at -78°C, the reaction was warmed to 0°C and stirred for 30 minutes. The solution was re-cooled to -78 °C and treated with aldehyde 2 (8.31 g, 42.81 mmol, 1.4 equiv) in CH 2 Cl 2 The solution in (25 mL) was worked up and stirred for 1 hour, warming to 0°C. After 1 hour at 0°C, sodium phosphate buffer (pH 7, 500 m...

Embodiment 3

[0252] Synthesis of Ring-Opening Candida Chain-Extension Intermediates.

[0253]To test the substrate scope of CrpTE and to generate novel candida macrolides, a scalable synthesis of NAc-activated ring-opening chain extension intermediates was developed, which is suitable for late diversification of unit A aryl groups. The analogs were synthesized convergently using two key intermediates including the unit AB and the unit CD-NAc. Unit AB was generated using chiral-assisted chemistry as well as the previously reported Suzuki coupling strategy. 38 Finally, Horner-Wadsworth-Emmons olefination (HWE) is used to form the key connection between units A and B. The unit CD with the NAc recognition element is generated by peptide coupling of commercially tractable amino acid derivatives.

[0254] For this, unit A ( image 3 ), which gave excellent yields and high dr (>20:1) to afford the desired (2R,3S) adduct. Subsequent silation with TBS triflate yields 3, and reductive cleavage o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides nostoc intermediates, nostoc analogs, and nostoc chimeric molecules useful in the treatment of cancer, as well as methods of producing these compounds and methods of treating cancer.

Description

[0001] Statement of Government Interest [0002] This invention was made with government support under GM076477 and GM118101 awarded by the National Institutes of Health. The government has certain rights in this invention. technical field [0003] The present disclosure generally relates to analogs of naturally occurring compounds and uses thereof, such as in methods of treating cancer, such as colorectal cancer, reducing the risk of cancer, or ameliorating the symptoms of cancer. Background technique [0004] Polyketide synthases (PKS), non-ribosomal peptide synthases (NRPS) and their hybrids (PKS / NRPS) are modular proteins that generate numerous complex natural products. These proteins select a relatively simple set of chemical building blocks (malonate, malonate derivatives and / or amino acids) and construct a variety of scaffolds with a wide range of biological activities. 1-2 As a broad class of these natural products, macrocycles 3 Contains constrained ring structu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K5/12C07D213/06C07D231/12A61K38/00A61P35/00
CPCC07D231/12C07D213/06C07D413/06
Inventor 大卫·H·谢尔曼詹妮弗·J·施密特
Owner RGT UNIV OF MICHIGAN